The specific aims of the Cancer Epidemiology Program are to evaluate the following factors in relation to cancer risk and survival: 1. Hormonal markers and other intermediate markers (e.g., metabolomics) as well as energy balance. 2. Genetic and epigenetic markers, with an emphasis on their interaction with environmental factors. Chronic inflammatory processes, as assessed through lifestyle, molecular markers and use of anti-inflammatory drugs. 3. Diet, including vitamin D, folate and other nutritional contributors to one-carbon metabolism. The Program focuses on exposures over the life course, including childhood and adolescence. Further, exposures are evaluated in relation to specific molecular characteristics of the tumor, analyses that can greatly enhance the understanding of etiologic pathways and provide support for causality. Cancer Epidemiology has been a Program since the formation of DF/HCC. The Program is led by S. Hankinson BWH) and W. Willett(HSPH) and includes 59 members representing five of the Harvard member institutions and 11 departments across Harvard Medical School and Harvard School of Public Health. The Program was rated """"""""outstanding"""""""" at its last review. Program members have $24.3 million in research funding (total costs), including $20.2 million in NCI funding and $3.7 million in other peer reviewed funding. Program members published 1,295 papers (2006 to 2010). Of these, ,30% were intra-programmatic, 43% of these were interprogrammatic collaborations and 35% were inter-institutional.
The Cancer Epidemiology Program focuses on determining and quantifying the role of lifestyle factors (such as diet and physical activity), other environmental factors, genetics and epigenetics in cancer incidence and survival. The overall goal of the Program is to find the means to reduce the occurrence of cancer and to improve the survival of patients with cancer.
|Agoston, Agoston T; Pham, Thai H; Odze, Robert D et al. (2018) Columnar-Lined Esophagus Develops via Wound Repair in a Surgical Model of Reflux Esophagitis. Cell Mol Gastroenterol Hepatol 6:389-404|
|Barber, Lauren; Gerke, Travis; Markt, Sarah C et al. (2018) Family History of Breast or Prostate Cancer and Prostate Cancer Risk. Clin Cancer Res 24:5910-5917|
|Kwee, Brian J; Budina, Erica; Najibi, Alexander J et al. (2018) CD4 T-cells regulate angiogenesis and myogenesis. Biomaterials 178:109-121|
|Madsen, Thomas; Braun, Danielle; Peng, Gang et al. (2018) Efficient computation of the joint probability of multiple inherited risk alleles from pedigree data. Genet Epidemiol 42:528-538|
|Chen, Jingjing; Guccini, Ilaria; Di Mitri, Diletta et al. (2018) Compartmentalized activities of the pyruvate dehydrogenase complex sustain lipogenesis in prostate cancer. Nat Genet 50:219-228|
|Li, Andrew G; Murphy, Elizabeth C; Culhane, Aedin C et al. (2018) BRCA1-IRIS promotes human tumor progression through PTEN blockade and HIF-1? activation. Proc Natl Acad Sci U S A 115:E9600-E9609|
|McBrayer, Samuel K; Mayers, Jared R; DiNatale, Gabriel J et al. (2018) Transaminase Inhibition by 2-Hydroxyglutarate Impairs Glutamate Biosynthesis and Redox Homeostasis in Glioma. Cell 175:101-116.e25|
|Stopsack, Konrad H; Gonzalez-Feliciano, Amparo G; Peisch, Samuel F et al. (2018) A Prospective Study of Aspirin Use and Prostate Cancer Risk by TMPRSS2:ERG Status. Cancer Epidemiol Biomarkers Prev 27:1231-1233|
|Kamareddine, Layla; Wong, Adam C N; Vanhove, Audrey S et al. (2018) Activation of Vibrio cholerae quorum sensing promotes survival of an arthropod host. Nat Microbiol 3:243-252|
|Schilit, Samantha L P; Morton, Cynthia C (2018) 3C-PCR: a novel proximity ligation-based approach to phase chromosomal rearrangement breakpoints with distal allelic variants. Hum Genet 137:55-62|
Showing the most recent 10 out of 411 publications